Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has ...
Shares of 89bio (NASDAQ:ETNB) were up 40% Monday afternoon, stoked by positive data for Akero Therapeutics' (NASDAQ:AKRO) drug efruxifermin in the treatment of compensated liver cirrhosis due to MASH.
Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class oral MASH therapy designed to address unmet needs in MASH through a unique energy expenditure approach - ...
Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire ...
QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating ...
Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in ...
Please provide your email address to receive an email when new articles are posted on . Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, ...
Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a ...
Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) after 36 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results